Objective: To explore the evaluation value of plasma fibrinogen (FIB) and phenylacetylglutamine (PAGln) for cardiogenic cerebral embolism (CCE) in non-valvular atrial fibrillation (NVAF). Methods: A total of 132 patients with NVAF were divided into CCE group (n=50) and non-CCE group (n=82) according to the occurrence of CCE. A healthy control group (n=50) was also set up. The baseline data and levels of plasma FIB and PAGln in the three groups were compared, and their correlation with clinical indexes was analyzed. Logistic regression analysis was used to identify the risk factors that affect the occurrence of CCE, and ROC curves were used to evaluate the predictive power of these factors on CCE. Results: FIB, PAGln, CHA?DS?-VASc score, NT-proBNP, D-dimer, Hcy, LAD and LAVI in CCE group were higher than those in non-CCE group and control group (P<0.05). There was a positive correlation between plasma PAGln levels and FIB in 132 patients with NVAF (P<0.05). Plasma PAGln and FIB were positively correlated with CHA?DS?-VASc score, NT-proBNP, D-dimer, Hcy, LAD, and LAVI (P<0.05). The increased PAGln, FIB and LAD were all independent risk factors of CCE (P<0.05). AUC values of FIB and PAGln for predicting CCE were 0.855 and 0.889, respectively. AUC, sensitivity and specificity of combined detection were 0.901, 82.00% and 89.02%, respectively (P < 0.05). Conclusion: The levels of plasma FIB and PAGln are increased in patients with NVAF and CCE. Combined detection of the two indexes has higher predictive value in CCE, which is conducive to evaluation of early clinical risk and intervention.